Jay Ramsinghani Joins Arcutis as Vice President of Commercial Strategy and Operations
27 May 2020 - 11:00PM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing and commercializing
treatments for unmet needs in immune-mediated dermatological
diseases and conditions, or immuno-dermatology, today announced
that Jay Ramsinghani has joined the company as Vice President of
Commercial Strategy and Operations. In this new role, Mr.
Ramsinghani will be responsible for Arcutis’ commercial operations
efforts as the Company prepares for the potential future
commercialization of its product candidates.
“Jay is a highly accomplished commercial
operations executive with over 18 years of biopharmaceutical
industry and consulting experience, much of which have been
specifically focused on the dermatology market,” said Ken Lock,
Arcutis’ Chief Commercial Officer. “Jay’s previous success in
building sales and marketing operations functions from the ground
up will be instrumental as we transform Arcutis from a research and
development organization into a fully-integrated commercial
dermatology company.”
Prior to joining Arcutis, Mr. Ramsinghani was
Senior Vice President Commercial Operations and Strategic Planning
at Alastin, where he built the commercial operations infrastructure
to support the organization’s high growth. He was also involved in
assessing and implementing partnerships, international expansion
planning, and corporate strategy projects. Prior to that, he led
the commercial operations group at Kythera Biopharmaceuticals
(acquired by Allergan) in advance of the KYBELLA® launch. Earlier
in his career, Mr. Ramsinghani was an Associate Principal with ZS
Associates, a global management consulting firm specializing in
healthcare sales and marketing strategy, where he managed multiple
client relationships and project teams. While at ZS Associates, he
supported his healthcare clients to launch or improve performance
of their products. Mr. Ramsinghani received his B.S. in Chemical
Engineering from the University of Arizona and his M.B.A. (with
distinction) from the Kellogg School of Management at Northwestern
University.
About Arcutis - Bioscience,
applied to the skin.
Arcutis is a late-stage biopharmaceutical
company focused on developing and commercializing treatments for
unmet needs in immune-mediated dermatological diseases and
conditions, or immuno-dermatology. Arcutis exploits recent
innovations in inflammation and immunology to develop potential
best-in-class therapies against validated biological targets,
leveraging our deep development, formulation and commercialization
expertise to bring to market novel dermatology treatments, while
maximizing our probability of technical success and financial
resources. Arcutis is currently developing four novel compounds,
including topical roflumilast cream (ARQ-151), topical roflumilast
foam (ARQ-154), ARQ-252, and ARQ-255 for multiple indications,
including psoriasis, atopic dermatitis, seborrheic dermatitis,
eczema, vitiligo, and alopecia areata. For more information, please
visit www.arcutis.com or follow the Company on LinkedIn.
Investors and Media:Heather
Rowe ArmstrongVice President, Investor Relations & Corporate
Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Oct 2023 to Oct 2024